Convergent evolution of SARS-CoV-2 XBB lineages on receptor-binding domain 455–456 synergistically enhances antibody evasion and ACE2 binding

Author:

Jian FanchongORCID,Feng Leilei,Yang Sijie,Yu Yuanling,Wang Lei,Song Weiliang,Yisimayi Ayijiang,Chen Xiaosu,Xu Yanli,Wang Peng,Yu Lingling,Wang Jing,Liu Lu,Niu Xiao,Wang Jing,Xiao Tianhe,An Ran,Wang Yao,Gu Qingqing,Shao Fei,Jin Ronghua,Shen Zhongyang,Wang Youchun,Wang Xiangxi,Cao YunlongORCID

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) XBB lineages have achieved dominance worldwide and keep on evolving. Convergent evolution of XBB lineages on the receptor-binding domain (RBD) L455F and F456L is observed, resulting in variants with substantial growth advantages, such as EG.5, FL.1.5.1, XBB.1.5.70, and HK.3. Here, we show that neutralizing antibody (NAb) evasion drives the convergent evolution of F456L, while the epistatic shift caused by F456L enables the subsequent convergence of L455F through ACE2 binding enhancement and further immune evasion. L455F and F456L evade RBD-targeting Class 1 public NAbs, reducing the neutralization efficacy of XBB breakthrough infection (BTI) and reinfection convalescent plasma. Importantly, L455F single substitution significantly dampens receptor binding; however, the combination of L455F and F456L forms an adjacent residue flipping, which leads to enhanced NAbs resistance and ACE2 binding affinity. The perturbed receptor-binding mode leads to the exceptional ACE2 binding and NAb evasion, as revealed by structural analyses. Our results indicate the evolution flexibility contributed by epistasis cannot be underestimated, and the evolution potential of SARS-CoV-2 RBD remains high.

Funder

Ministry of Science and Technology of the People's Republic of China

Changping Laboratory

Excellent Young Scientists Fund

Publisher

Public Library of Science (PLoS)

Subject

Virology,Genetics,Molecular Biology,Immunology,Microbiology,Parasitology

Reference45 articles.

1. The evolution of SARS-CoV-2.;PV Markov;Nature Reviews Microbiology.,2023

2. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection;Y Cao;Nature,2022

3. Further humoral immunity evasion of emerging SARS-CoV-2 BA.4 and BA.5 subvariants;F Jian;The Lancet Infectious Diseases,2022

4. Characterization of the enhanced infectivity and antibody evasion of Omicron BA.2.75;Y Cao;Cell Host Microbe,2022

5. Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate;R Uraki;The Lancet Infectious Diseases,2023

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3